Oklahoma Medicaid coverage for Zepbound (Osa)

Medicaid

Covered with requirements

What you need to qualify

Age 18 and older
BMI of 30 or higher
A1C no higher than 6.5%
Diagnosed obstructive sleep apnea (AHI of 15 or higher)
Lab results confirming eligibility
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

OSA — initial approval

All of:

FDA approved indication of moderate to severe OSA in members with obesity
Member is 18 years of age or older
Moderate to severe OSA defined as AHI >= 15 determined by PSG or technically adequate HSAT (AHI value must be provided)
BMI >= 30 kg/m2
No central or mixed sleep apnea
No T1DM or T2DM
HbA1c < 6.5%
Not using Zepbound in combination with other tirzepatide-containing products or any GLP-1 receptor agonist
Diet and exercise used in conjunction (clinical documentation required)

Documentation to bring

AHI value from polysomnography (PSG) or home sleep apnea testing (HSAT) with a technically adequate device confirming AHI >= 15
Baseline BMI >= 30 kg/m2
HbA1c lab result confirming < 6.5%
Clinical documentation (e.g., office notes) of diet and exercise program
Confirmation member does not have central or mixed sleep apnea
Confirmation member does not have T1DM or T2DM
Confirmation member will not use Zepbound in combination with other tirzepatide-containing products or any GLP-1 receptor agonist
For Zepbound vials: patient-specific, clinically significant reason why member cannot use the pen or KwikPen formulation

Quantity limits

all pen and vial strengths — 4 pens or vials (2mL) per 28 days
KwikPen — 1 KwikPen (2.4mL) per 28 days

Approval and renewal

Initial approval: 2 months
Renewal: every 12 months
To renew, the plan looks for Member is tolerating maintenance dosing and adherent to therapy; clinical improvement of OSA (e.g., patient-reported improvement in daytime sleepiness, partner-reported reduction of snoring episodes or pauses in breathing, reduction of AHI events); member has not developed T1DM or T2DM; member is continuing a reduced calorie diet and increased physical activity in conjunction with Zepbound and staying on a maintenance dose of at least 5 mg.

Not covered when

Type 2 diabetes mellitus (T2DM excluded; HbA1c must be <6.5%)
Central or mixed sleep apnea
Concurrent use with other tirzepatide-containing products or any GLP-1 receptor agonist
Obese members without OSA will not be approved
Members who cannot tolerate dose escalation to at least 5mg after additional 8-week approval will not be approved for continuation
Zepbound should be discontinued if member cannot tolerate at least 5mg once weekly maintenance dosing
Zepbound vials are non-preferred over pens and KwikPens; vials require patient-specific justification
Type 1 diabetes

Policy note: Initial approvals are for 8-week titration periods per dose; a separate PA must be submitted for each dose. An additional 8 weeks per dose may be approved for intolerable adverse effects during escalation with documentation. Members who cannot tolerate escalation to at least 5mg after additional 8-week approval will not be approved for continuation. Subsequent (maintenance) approvals are for 1 year for maintenance doses of 5mg to 15mg. OSA must be moderate to severe (AHI >= 15). PAP/CPAP trial is NOT required by this policy. Last modified date on the Metabolic Disorders page is April 24, 2026.

verified June 4, 2026 · source: policy-385.html